Companies promoting successful Covid-19 treatment candidates are gaining traction in the healthcare industry and attracting investment. Numerous firms of various sizes are developing investigational therapies at a rapid rate. This includes biotech firms like iBio, which specialises in the creation and manufacturing of antibodies and vaccines in development. Following its inclusion in the Russell 2000 and Russell 3000 indices in July of last year, iBio’s stock price skyrocketed.
Investor optimism dropped immediately after due to a lack of news from its Covid-19 vaccine candidates, resulting in a 75 percent drop in the biotech stock. Exclusive licencing deals and positive preclinical studies involving the company’s most promising candidates have sparked a brief resurgence in investor interest. Is this a precursor to future growth? In its current pipeline, iBio has four candidates, three of which are related to human diseases. It is also working on a swine fever vaccine.
The findings support the notion that current vaccines targeting the spike (S) protein can be successful, but that their effectiveness may decline with time, necessitating supplementary shots. The vaccination could be more effective and long-lasting if it focuses on the N protein in conjunction with the S protein. RTX-003 (renamed IBIO-101), an antibody developed by RubrYc Therapeutics that targets regulatory T cells (Tregs) utilised in cancer immunotherapy, is a second candidate in the pipeline that the business is optimistic about.